Alzamend Neuro is a specialty pharmaceutical company engaged in the development and commercialization of patented intellectual property to prevent, treat and cure Alzheimer's disease ("Alzheimer's" or "AD"). Co. has licensed an immunotherapy vaccine peptide that works both as a treatment and vaccine against Alzheimer's and an ionic cocrystal of lithium to mitigate extreme agitation and forestall other deterioration as displayed by patients with up to moderate AD and possibly other neurodegenerative diseases. Co. devotes substantially all its efforts towards research and development of its Technology and raising capital. The ALZN average annual return since 2021 is shown above.
The Average Annual Return on the ALZN average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ALZN average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ALZN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|